Steritas_ClinicalScience_1920x820pxl_Avacopan

Steritas GTI

Based on data-driven, peer-reviewed research.

Publications

From the first publication of the GTI in 2017 (“Development of the Glucocorticoid Toxicity Index (GTI 1.0) Using Multi-criteria Decision Analysis”), use of the GTI and study publications have continued to grow. The earliest adopters of the technology have begun to report their findings. The GTI has become an essential clinical outcome assessment in nearly 20 of the most common inflammatory diseases. 

 

The February 2021 New England Journal of Medicine article “Avacopan for the Treatment of ANCA-Associated Vasculitis” is a foundational study that describes the use of the GTI to demonstrate reduced toxicity of avacopan as an adjunct treatment with prednisone compared to prednisone alone.

Avacopan for the Treatment of ANCA-Associated Vasculitis.
The New England Journal of Medicine

Read more
The Role of Quantification of Glucocorticoid-associated Toxicity in Severe Asthma.
Journal of Cellular Immunology

Read more
The Vexed Problem of Corticosteroid Toxicity in Asthma: Time for Standardized Assessment.
The Journal of Allergy and Clinical Immunology

Read more
Glucocorticoid toxicity reduction with Mepolizumab using the glucocorticoid toxicity index

Read more
Evaluation of the toxicity of glucocorticoids in patients with autoimmune blistering disease using the Glucocorticoid Toxicity Index: A cohort study
JAAD INT - VOLUME 6

Read more

Clinical evidence demonstrates the value of the GTI for drug developers and for patients

For drug developers, the ADVOCATE trial that enabled FDA approval of avacopan to treat ANCA-associated vasculitis reported the GTI as a critical secondary endpoint in demonstrating avacopan efficacy. For patients, an asthma cohort study determined that measuring GC toxicity systematically with the GTI may help determine which patients would derive the most benefit from new steroid-sparing therapies

 

Avacopan Clinical Trial Data Real world study of Asthma

Could the Steritas GTI be a useful efficacy and safety outcome measure in your next clinical trial?
Register to attend our webinar.

Register today

Clinical Trials

Clear Filters
Polymyalgia Rheumatica

Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

Phase 3 – A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica Recruitment Status: Terminated (Protracted recruitment timeline exacerbated by COVID-19 ...
Polymyalgia Rheumatica, Inflammatory Rheumatism, Giant Cell Arteritis, Idiopathic Inflammatory Myopathies, ANCA Associated Vasculitis, Systemic Autoimmune Disease

PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS (PRODIGIOUS)

Observational Cohort Prospective Recruitment Status: Not yet recruiting Sponsor: University Hospital, Brest Study Population: Patients usually treated with prolonged glucocorticoid therapy in the field of rheumatology.  Primary Outcome Measures: ...
Rheumatoid Arthritis, Vasculitis, Systemic Lupus Erythematosus

Monıtorıng Glucocortıcoıd Treatment In Patıents Followed In Rheumatology Clınıc.

Recruitment Status: Sponsor: Study Population:  Primary Outcome Measures: Secondary Primary Outcome Measures:
Polymyalgia Rheumatica, Giant Cell Arteritis

Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

Recruitment Status: Terminated (Protracted recruitment timeline exacerbated by COVID-19 pandemic)  Sponsor: Sanofi  Study Population:  118 participants Primary Outcome Measures: To evaluate the efficacy of KEVZARA (sarilumab) in patients with ...
Giant Cell Arteritis

Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

Recruitment Status: Sponsor: Study Population:  Primary Outcome Measures: Secondary Primary Outcome Measures: